IP Verse

Abraxis Bioscience competitive analysis

Loading summary...

Latest patents of Abraxis Bioscience opposed by its competitors

Explore Abraxis Bioscience's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP2943192	Sep 29, 2021	Methods Of Treating Pancreatic Cancer	4
EP3248600	Jun 24, 2020	Combinations And Modes Of Administration Of Therapeutic Agents And Combination Therapy	2
EP2968254	Apr 22, 2020	Methods Of Treating Lung Cancer	1
EP2575803	Jul 26, 2017	Methods Of Treating Bladder Cancer	1

Latest publications and patents of Abraxis Bioscience New

Explore the latest publications and patents granted to Abraxis Bioscience, showcasing their recent innovations and technological advancements.

Last updated on: Oct 22, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Abraxis Bioscience
EP2943192	Sep 29, 2021	Methods Of Treating Pancreatic Cancer	Revoked
EP3248600	Jun 24, 2020	Combinations And Modes Of Administration Of Therapeutic Agents And Combination Therapy	Revoked
EP2968254	Apr 22, 2020	Methods Of Treating Lung Cancer	Revoked
EP1861070	Jan 17, 2018	Drugs With Improved Hydrophobicity For Incorporation In Medical Devices	No Opposition Filed Within Time Limit
EP2575803	Jul 26, 2017	Methods Of Treating Bladder Cancer	Revoked

Latest PTAB cases involving Abraxis Bioscience

Discover the latest PTAB cases involving Abraxis Bioscience, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 28, 2025

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Abraxis Bioscience
IPR2018-00151	Nov 9, 2017	APOTEX	ABRAXIS BIOSCIENCE	Terminated
IPR2018-00152	Nov 9, 2017	APOTEX	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2018-00153	Nov 9, 2017	APOTEX	ABRAXIS BIOSCIENCES	Terminated-Settled
IPR2018-00162	Nov 9, 2017	CIPLA	ABRAXIS BIOSCIENCES	Institution Denied
IPR2018-00163	Nov 9, 2017	CIPLA	ABRAXIS BIOSCIENCES	Institution Denied
IPR2017-01100	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Institution Denied
IPR2017-01101	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2017-01103	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2017-01104	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled

Peer Comparison New

IP litigation analysis comparing Abraxis Bioscience with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
ABRAXIS BIOSCIENCE	-	8	-	6
ACTAVIS	-	-	5	-
GENERICS UK	214	-	-	-
TEVA PHARMACEUTICALS	209	16	-	12